Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Chronic Graft-versus-host Disease (cGVHD)
90%
Acute Myeloid Leukemia
47%
Paroxysmal Nocturnal Hemoglobinuria
45%
Older Adults
40%
Hematopoietic Cell Transplantation
36%
Overall Survival
31%
Cynomolgus Macaque
30%
Hematopoietic Stem Cell Transplantation
27%
Transplantation
25%
Hematological Malignancies
24%
Conditioning Regimen
23%
Clinical Outcomes
22%
Graft-versus-host Disease (GvHD)
21%
HLA-matched Donor
21%
Leukemia
21%
Neoplasms
20%
Phase 1 Trial
20%
Venetoclax
20%
Cell Therapy
20%
Single Institution
20%
Living with
20%
Granulocyte Colony-stimulating Factor (G-CSF)
20%
Transplantation Therapy
20%
Practice Guidelines
20%
Itacitinib
20%
Resistance Training
20%
Transplant Outcomes
19%
Myelodysplasia
19%
Bone Marrow Failure
17%
Older Cancer Survivors
16%
Engraftment
16%
Non-relapse Mortality
15%
95% Confidence Interval
15%
Older Patients
15%
Severe Aplastic Anemia
15%
Lymphocryptovirus
15%
Inherited Bone Marrow Failure Syndromes
15%
Donor-derived
15%
Peripheral Blood
14%
Pretransplant
14%
Bortezomib
14%
Placebo
13%
Relapse Rate
13%
Bone Marrow
13%
Risk Factors
13%
Corticosteroids
13%
Allogeneic Hematopoietic Cell Transplant
13%
High Risk
12%
Immunosuppressive Therapy
12%
Medicine and Dentistry
Hematopoietic Cell
63%
Malignant Neoplasm
47%
Cell Transplantation
39%
Paroxysmal Nocturnal Hemoglobinuria
38%
Hematopoietic Stem Cell Transplantation
34%
Acute Myeloid Leukemia
28%
Resistance Training
26%
Diseases
25%
Aplastic Anemia
23%
Myelodysplastic Syndrome
23%
Allograft
22%
Overall Survival
22%
Hematologic Malignancy
22%
Chronic Graft Versus Host Disease
20%
Cell Therapy
20%
Graft Failure
20%
Leukemia Prevention
20%
Bone Marrow Failure
19%
Quality of Life
17%
Stem Cell
14%
Marrow Failure Syndrome
14%
Graft Versus Host Reaction
13%
Frailty
12%
Neoplasm
12%
Engraftment
12%
Recurrence Risk
12%
Serositis
11%
Oncology
11%
Risk Stratification
11%
Scoping Review
11%
Granulocyte Colony Stimulating Factor
10%
Hazard Ratio
10%
Symptomatic Treatment
10%
Diffuse Large B-Cell Lymphoma
10%
Pericarditis
10%
COVID-19
10%
Surgical Oncology
10%
Acute Leukemia
10%
Whole Body Radiation
10%
Lymphedema
10%
Multiple Myeloma
10%
Brain Disease
10%
Patient-Reported Outcome
10%
Human Parainfluenza Virus 3
10%
Chronic Myelomonocytic Leukemia
10%
Fludarabine
10%
Busulfan
10%
Geriatric Assessment
10%
Cancer
10%
Chimeric Antigen Receptor T-Cell Immunotherapy
10%
Immunology and Microbiology
Hematopoietic Cell
52%
Acute Graft Versus Host Disease
51%
Cell Transplantation
46%
Macaca fascicularis
35%
Hematopoietic Stem Cell Transplantation
33%
Graft-Versus-Host Disease
32%
Chronic Graft Versus Host Disease
32%
Allogeneic Hematopoietic Stem Cell Transplantation
30%
Allogeneic Stem Cell Transplantation
30%
Infectious Disease
23%
Infection
23%
Macaca
21%
Overall Survival
20%
Granulocyte Colony-Stimulating Factor
20%
Engraftment
15%
Stem Cell Transplantation
15%
Lymphocryptovirus
15%
Virus
15%
Lymphoproliferative Disorders
12%
Immunosuppressive Therapy
12%
Simian Immunodeficiency Virus
11%
Human Immunodeficiency Virus
10%
Next Generation Sequencing
10%
Myeloid
10%
Pericarditis
10%
Hematopoiesis
10%
Autologous Stem Cell Transplantation
10%
Amyloidosis
10%
Angiogenic Factor
10%
Multiple Drug Dose
10%
Opportunistic Infection
10%
Stem Cell Transplant
10%
Drug Megadose
10%
CD34
10%
Human Parainfluenza Virus 3
10%
Allograft
10%
Eculizumab
10%
CCR5
7%
Steroid
7%
Lymph Node
6%
Epstein Barr Virus
5%
Viral Replication
5%
Light Chain
5%
Yellow Fever
5%
Polyomavirus
5%
Immune System
5%
Complement Inhibition
5%